Sangamo Therapeutics
Sangamo Therapeutics and Genentech team up to develop genomic medicines for neurodegenerative diseases
August 7, 2024Research and Development Genentech, Neurology, Sangamo Therapeutics, genomic medicine, neurodegenerative diseases
Genomic medicine company Sangamo Therapeutics and Genentech have entered into a licensing agreement to develop intravenously administered genomic medicines to …
Pfizer and Sangamo’s haemophilia gene therapy shows increased factor VIII levels
December 9, 2019Manufacturing and Production, Sales and Marketing American Society of Hematology, Pfizer, Sangamo Therapeutics, hematology
Pfizer and Sangamo Therapeutics have revealed that their investigational gene therapy, SB-525, sustained increased factor VIII (FVIII) levels in patients …
Gilead seals $3bn deal, hoping for off-the-shelf CAR-T
February 23, 2018Medical Communications, Sales and Marketing CAR-T, Gilead, Kite, Sangamo Therapeutics, biotech, drugs, pharma, pharmaceutical
The expense and laborious process involved in bringing CAR-T therapies to patients was used a key reason for the high …
Sangamo secures FDA’s Fast Track Designation for haemophilia candidate
May 17, 2017Research and Development, Sales and Marketing FDA, Pfizer, Sangamo Therapeutics
Sangamo Therapeutics has announced that the FDA has granted its cDNA gene therapy candidate for haemophilia A Fast Track Designation. …
Latest content
Scots neonatal innovations target hearing loss and earlier care
August 28, 2026
Agentis Health Group acquires Clinical Pharmacist Solutions
August 26, 2026
